Alliant Techsystems | *average Indexing Innovation Technology Review has teamed with CHI Research of Haddon Heights, NJ, to produce the Patent Scorecard, an industry-by-industry ranking of corporate patent portfolios. CHI combines the number of a firm’s patents with other indicators to flesh out this deeper picture of innovation. Here are the specifics: Technology Strength: This figure, the basis of the rankings, provides an overall assessment of a firm’s intellectual-property power. It is calculated by multiplying the number of a company’s U.S. patents by its Current Impact Index (see below). Number of Patents: The total number of U.S. patents awarded, excluding design and other special-case inventions. Current Impact Index: This measure showcases the broader significance of a company’s patents by examining how often its U.S. patents from the previous five years are cited as “prior art” in the current year’s batch. A value of 1.0 represents average citation frequency; so 1.4 would indicate a company’s patents were cited 40 percent more often than average, and so on. Science Linkage: Patents sometimes cite scientific papers as prior art. This value shows the average number of science references listed in a company’s U.S. patents. A high figure indicates the company is closer to the cutting edge than its competitors. Technology Cycle Time: An indicator of a firm’s speed in turning leading-edge technology into intellectual property, defined as the median age (in years) of the U.S. patents cited as prior art in the company’s patents. Automotive | |
Company |
DaimlerChrysler | 344/8 | 0.26 | TRW | Bosch | Denso Honda Toyota Motor General Motors Ford Motor Nissan Motor Yazaki Eaton Yamaha | Aisin Seiki | Lear | Delphi Automotive Systems | ITT | Fiat | Breed Technologies | *average Indexing Innovation Technology Review has teamed with CHI Research of Haddon Heights, NJ, to produce the Patent Scorecard, an industry-by-industry ranking of corporate patent portfolios. CHI combines the number of a firm’s patents with other indicators to flesh out this deeper picture of innovation. Here are the specifics: Technology Strength: This figure, the basis of the rankings, provides an overall assessment of a firm’s intellectual-property power. It is calculated by multiplying the number of a company’s U.S. patents by its Current Impact Index (see below). Number of Patents: The total number of U.S. patents awarded, excluding design and other special-case inventions. Current Impact Index: This measure showcases the broader significance of a company’s patents by examining how often its U.S. patents from the previous five years are cited as “prior art” in the current year’s batch. A value of 1.0 represents average citation frequency; so 1.4 would indicate a company’s patents were cited 40 percent more often than average, and so on. Science Linkage: Patents sometimes cite scientific papers as prior art. This value shows the average number of science references listed in a company’s U.S. patents. A high figure indicates the company is closer to the cutting edge than its competitors. Technology Cycle Time: An indicator of a firm’s speed in turning leading-edge technology into intellectual property, defined as the median age (in years) of the U.S. patents cited as prior art in the company’s patents. Biotech/Pharmaceuticals | |
Company |
GlaxoSmithKline | Pharmacia | Isis Pharmaceuticals | Merck | Pfizer | Aventis | Schering | Roche | Eli Lilly | AstraZeneca | Novartis | Abbott Laboratories | Novo Nordisk | Affymetrix | Bristol-Myers Squibb | BioNumerik Pharmaceuticals | Alliance Pharmaceutical | General Hospital | Takeda Chemical | Xoma | American Home Products | Schering-Plough | Incyte Genomics | Alza | *average Indexing Innovation Technology Review has teamed with CHI Research of Haddon Heights, NJ, to produce the Patent Scorecard, an industry-by-industry ranking of corporate patent portfolios. CHI combines the number of a firm’s patents with other indicators to flesh out this deeper picture of innovation. Here are the specifics: Technology Strength: This figure, the basis of the rankings, provides an overall assessment of a firm’s intellectual-property power. It is calculated by multiplying the number of a company’s U.S. patents by its Current Impact Index (see below). Number of Patents: The total number of U.S. patents awarded, excluding design and other special-case inventions. Current Impact Index: This measure showcases the broader significance of a company’s patents by examining how often its U.S. patents from the previous five years are cited as “prior art” in the current year’s batch. A value of 1.0 represents average citation frequency; so 1.4 would indicate a company’s patents were cited 40 percent more often than average, and so on. Science Linkage: Patents sometimes cite scientific papers as prior art. This value shows the average number of science references listed in a company’s U.S. patents. A high figure indicates the company is closer to the cutting edge than its competitors. Technology Cycle Time: An indicator of a firm’s speed in turning leading-edge technology into intellectual property, defined as the median age (in years) of the U.S. patents cited as prior art in the company’s patents. Chemicals | |
Company |
Procter & Gamble | 3M | DuPont | BASF | Bayer | Bridgestone | Dow Chemical | Cabot | Shin-Etsu Chemical | Agfa | E.ON | Ciba Specialty Chemicals | L’Air Liquide | Rohm and Haas | Air Products & Chemicals | Dow Corning | Mitsubishi Chemical | Sumitomo Chemical | *average Indexing Innovation Technology Review has teamed with CHI Research of Haddon Heights, NJ, to produce the Patent Scorecard, an industry-by-industry ranking of corporate patent portfolios. CHI combines the number of a firm’s patents with other indicators to flesh out this deeper picture of innovation. Here are the specifics: Technology Strength: This figure, the basis of the rankings, provides an overall assessment of a firm’s intellectual-property power. It is calculated by multiplying the number of a company’s U.S. patents by its Current Impact Index (see below). Number of Patents: The total number of U.S. patents awarded, excluding design and other special-case inventions. Current Impact Index: This measure showcases the broader significance of a company’s patents by examining how often its U.S. patents from the previous five years are cited as “prior art” in the current year’s batch. A value of 1.0 represents average citation frequency; so 1.4 would indicate a company’s patents were cited 40 percent more often than average, and so on. Science Linkage: Patents sometimes cite scientific papers as prior art. This value shows the average number of science references listed in a company’s U.S. patents. A high figure indicates the company is closer to the cutting edge than its competitors. Technology Cycle Time: An indicator of a firm’s speed in turning leading-edge technology into intellectual property, defined as the median age (in years) of the U.S. patents cited as prior art in the company’s patents. | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | |
|